Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial

References

• Allott K, Liu P, Proffitt T-M, Killackey E. 2011. Cognition at illness onset as a predictor of later functional outcome in early psychosis: systematic review and methodological critique. Schizophr Res. 125:221–235.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. 1994. Diagnostic and Stastistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Press.
   Google Scholar
• Bado P, Madeira C, Vargas-Lopes C, Moulin T, Wasilewska-Sampaio A, Maretti L, et al. 2011. Effects of low-dose D-serine on recognition and working memory in mice. Psychopharmacology (Berl). 218:461–470.
   PubMed Web of Science ®Google Scholar
• Balu DT, Coyle JT. 2014. Chronic D-serine reverses arc expression and partially rescues dendritic abnormalities in a mouse model of NMDA receptor hypofunction. Neurochem Int. 75:76–78.
   PubMed Web of Science ®Google Scholar
• Barnes TR. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry. 154:672–676.
   PubMed Web of Science ®Google Scholar
• Bell MD, Mishara AL. 2006. Does negative symptom change relate to neurocognitive change in schizophrenia? Implications for targeted treatments. Schizophr Res. 81:17–27.
   PubMed Web of Science ®Google Scholar
• Berman I, Viegner B, Merson A, Allan E, Pappas D, Green AI. 1997. Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia. Schizophr Res. 25:1–10.
   PubMed Web of Science ®Google Scholar
• Brahmachari S, Jana A, Pahan K. 2009. Sodium benzoate, a metabolite of cinnamon and a food additive, reduces microglial and astroglial inflammatory responses. J Immunol. 183:5917–5927.
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, et al. 2007. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 164:1593–1602.
   PubMed Web of Science ®Google Scholar
• Burnet PW, Anderson PN, Chen L, Nikiforova N, Harrison PJ, Wood MJ. 2011. D-amino acid oxidase knockdown in the mouse cerebellum reduces NR2A mRNA. Mol Cell Neurosci. 46:167–175.
   PubMed Web of Science ®Google Scholar
• Carrión RE, Goldberg TE, McLaughlin D, Auther AM, Correll CU, Cornblatt BA. 2011. Impact of neurocognition on social and role functioning in individuals at clinical high risk for psychosis. Am J Psychiatry. 168:806–813.
   PubMed Web of Science ®Google Scholar
• Chen WJ, Liu SK, Chang CJ, Lien YJ, Chang YH, Hwu HG. 1998. Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients. Am J Psychiatry. 155:1214–1220.
   PubMed Web of Science ®Google Scholar
• Corbera S, Wexler BE, Ikezawa S, Bell MD. 2013. Factor Structure of Social Cognition in Schizophrenia: Is Empathy Preserved? Schizophr Res Treatment. 2013:409205
   PubMedGoogle Scholar
• Couture SM, Penn DL, Roberts DL. 2006. The functional significance of social cognition in schizophrenia: a review Schizophr Bull. 32:s44–s63.
   Google Scholar
• D'Souza DC, Radhakrishnan R, Perry E, Bhakta S, Singh NM, Yadav R, et al. 2013. Feasibility, safety, and efficacy of the combination of d-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study. Neuropsychopharmacology. 38:492–503.
   PubMed Web of Science ®Google Scholar
• Errico F, Napolitano F, Squillace M, Vitucci D, Blasi G, de Bartolomeis A, et al. 2013. Decreased levels of D-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia. J Psychiatr Res. 47:1432–1437.
   PubMed Web of Science ®Google Scholar
• FirstWord Pharma. 2014. Roche's bitopertin fails to meet main goals of late-stage schizophrenia trials; January 21st, 2014: [Available from: http://www.firstwordpharma.com/node/1180713#axzz3En2j9x4U.
   Google Scholar
• Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. 2010. International consensus study of antipsychotic dosing. Am J Psychiatry. 167:686–693.
   PubMed Web of Science ®Google Scholar
• Green MF, Kern RS, Braff DL, Mintz J. 2000. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull. 26:119–136.
   PubMed Web of Science ®Google Scholar
• Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, et al. 2004. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 56:301–307.
   PubMed Web of Science ®Google Scholar
• Green MF, Olivier B, Crawley JN, Penn DL, Silverstein S. 2005. Social cognition in schizophrenia: recommendations from the measurement and treatment research to improve cognition in schizophrenia new approaches conference. Schizophr Bull. 31:882–887.
   PubMed Web of Science ®Google Scholar
• Green MF, Schooler NR, Kern RS, Frese FJ, Granberry W, Harvey PD, et al. 2011. Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am J Psychiatry. 168:400–407.
   PubMed Web of Science ®Google Scholar
• Guy W. 1976. ECDEU Assessment Manual for Psychopharmacology: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs.
   Google Scholar
• Guy W. 2000. Clinical Global Impressions (CGI) Scale. Modified From: Rush J, et al. Psychiatric Measures. Washington DC: APA.
   Google Scholar
• Hashimoto K. 2014. Targeting of NMDA receptors in new treatments for schizophrenia. Expert Opin Ther Targets. 18:1049–1063.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Fujita Y, Horio M, Kunitachi S, Iyo M, Ferraris D, et al. 2009. Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol Psychiatry. 65:1103–1106.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Malchow B, Falkai P, Schmitt A. 2013. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci. 263:367–377.
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Durrant AR, Ermilov M, Javitt DC, Miya K, Mori H. 2015. Clinical and electrophysiological effects of D-serine in a schizophrenia patient positive for anti-N-methyl-D-aspartate receptor antibodies. Biol Psychiatry. 77:e27–e29.
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC. 2004. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry. 55:165–171.
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, et al. 2005. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry. 57:577–585.
   PubMed Web of Science ®Google Scholar
• Javitt DC. 2008. Glycine transport inhibitors and the treatment of schizophrenia. Biol Psychiatry. 63:6–8.
   PubMed Web of Science ®Google Scholar
• Javitt DC, Silipo G, Cienfuegos A, Shelley AM, Bark N, Park M, et al. 2001. Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol. 4:385–391.
   PubMed Web of Science ®Google Scholar
• Javitt DC, Zukin SR, Heresco-Levy U, Umbricht D. 2012. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull. 38:958–966.
   PubMed Web of Science ®Google Scholar
• Kantrowitz JT, Malhotra AK, Cornblatt B. 2010. High dose D-serine in the treatment of schizophrenia. Schizophr Res. 121:125–130.
   PubMed Web of Science ®Google Scholar
• Kasper S. 2006. Optimisation of long-term treatment in schizophrenia: Treating the true spectrum of symptoms. Eur Neuropsychopharmacol. 16:s135–s141.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 13:261–276.
   PubMed Web of Science ®Google Scholar
• Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, et al. 2008. The MATRICS Consensus Cognitive Battery, Part 2: Co-Norming and Standardization. Am J Psychiatry. 165:214–220.
   PubMed Web of Science ®Google Scholar
• Kern RS, Gold JM, Dickinson D, Green MF, Nuechterlein KH, Baade LE, et al. 2011. The MCCB Impairment Profile for Schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr Res. 126:124–131.
   PubMed Web of Science ®Google Scholar
• Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. 1994. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatry. 51:199–214.
   PubMed Web of Science ®Google Scholar
• Labrie V, Roder JC. 2010. The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia. Neurosci Biobehav Rev. 34:351-372.
   PubMed Web of Science ®Google Scholar
• Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. 2005. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry. 62:1196–1204.
   PubMed Web of Science ®Google Scholar
• Lane HY, Huang CL, Wu PL, Liu YC, Chang YC, Lin PY, et al. 2006. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry. 60:645–649.
   PubMed Web of Science ®Google Scholar
• Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, et al. 2013. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry. 70:1267–1275.
   PubMed Web of Science ®Google Scholar
• Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE. 2010. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol. 13:451–460.
   PubMed Web of Science ®Google Scholar
• Lane HY, Liu YC, Huang CL, Chang YC, Liau CH, Perng CH, et al. 2008. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry. 63:9–12.
   PubMed Web of Science ®Google Scholar
• Levin R, Dor-Abarbanel AE, Edelman S, Durrant AR, Hashimoto K, Javitt DC, et al. 2015. Behavioral and cognitive effects of the N-methyl-D-aspartate receptor co-agonist D-serine in healthy humans: Initial findings. J Psychiatr Res. 61:188–195.
   PubMed Web of Science ®Google Scholar
• Lin CH, Chen PK, Chang YC, Chuo LJ, Chen YS, Tsai GE, et al. 2014a. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: A randomized, double-blind, placebo-controlled trial. Biol Psychiatry. 75:678–685.
   PubMed Web of Science ®Google Scholar
• Lin CH, Tseng YL, Huang CL, Chang YC, Tsai GE, Lane HY. 2013. Synergistic effects of COMT and TPH2 on social cognition. Psychiatry. 76:273–294.
   PubMed Web of Science ®Google Scholar
• Lin CY, Tsai GE, Lane HY. 2014b. Assessing and treating cognitive impairment in schizophrenia: current and future. Curr Pharm Des. 20:5127–5138.
   PubMed Web of Science ®Google Scholar
• Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. 1987. The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand. 76:1–100.
   PubMed Web of Science ®Google Scholar
• Ma WF, Tsai GE, Chang JP-C, Lane HY. 2012. Reliability and validity of three Chinese-version tasks of Mayer-Salovey-Caruso Emotional Intelligence Test. J Clin Nurs. 19:2656–2658.
   Web of Science ®Google Scholar
• Matsuura A, Fujita Y, Iyo M, Hashimoto K. 2015. Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine. Acta Neuropsychiatr. 27:159–167.
   PubMed Web of Science ®Google Scholar
• Mayer JD, Salovey P, Caruso DR, Sitarenios G. 2003. Measuring emotional intelligence with the MSCEIT V2.0. Emotion. 3:97–105.
   PubMed Web of Science ®Google Scholar
• McBain CJ, Kleckner NW, Wyrick S, Dingledine R. 1989. Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in xenopus oocytes. Mol Pharmacol. 36:556–565.
   PubMed Web of Science ®Google Scholar
• McCleery A, Ventura J, Kern RS, Subotnik KL, Gretchen-Doorly D, Green MF, et al. 2014. Cognitive functioning in first-episode schizophrenia: MATRICS Consensus Cognitive Battery (MCCB) Profile of Impairment. Schizophr Res. 157:33–39.
   PubMed Web of Science ®Google Scholar
• Meltzer HY. 2013. Update on typical and atypical antipsychotic drugs. Annu Rev Med. 64:393–406.
   PubMed Web of Science ®Google Scholar
• Millan MJ, Agid Y, Brüne M, Bullmore ET, Carter CS, Clayton NS, et al. 2012. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov. 11:141–168.
   PubMed Web of Science ®Google Scholar
• Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman J, Keefe R. 2008. Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry. 165:978–987.
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Keefe RSE, Javitt DC. 2014. Cognitive deficits and poor functional outcomes in schizophrenia: clinical and neurobiological progress. Current Psychiatry. 13:s1–s11.
   Google Scholar
• Paoletti P, Bellone C, Zhou Q. 2013. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci. 14:383–400.
   PubMed Web of Science ®Google Scholar
• Papouin T, Ladépêche L, Ruel J, Sacchi S, Labasque M, Hanini M, et al. 2012. Synaptic and Extrasynaptic NMDA Receptors Are Gated by Different Endogenous Coagonists. Cell. 150:633–646.
   PubMed Web of Science ®Google Scholar
• Preskorn SH, Gawryl M, Dgetluck N, Palfreyman M, Bauer LO, Hilt D. 2014. Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract. 20:12–24.
   PubMed Web of Science ®Google Scholar
• Savilla K, Kettler L, Galletly C. 2008. Relationships Between Cognitive Deficits, Symptoms and Quality of Life in Schizophrenia. Aust N Z J Psychiatry. 42:496–504.
   PubMed Web of Science ®Google Scholar
• Sawa A. 2009. Cortical Development and Glutamatergic Dysregulation in Schizophrenia. Biol Psychiatry. 66:530–532.
   PubMed Web of Science ®Google Scholar
• Schultz SK, Andreasen NC. 1999. Schizophrenia. Lancet. 353:1425–1430.
   PubMed Web of Science ®Google Scholar
• Sergi MJ, Green MF, Widmark C, Reist C, Erhart S, Braff DL, et al. 2007. Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry. 164:1585–1592.
   PubMed Web of Science ®Google Scholar
• Simpson GM, Angus JW. 1970. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 212:11–19.
   PubMedGoogle Scholar
• Steiner J, Bogerts B, Sarnyai Z, Walter M, Gos T, Bernstein HG, et al. 2012. Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: Potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrity. World J Biol Psychiatry. 13:482–492.
   PubMed Web of Science ®Google Scholar
• Sternberg S. 1966. High-speed scanning in human memory. Science. 153:652–654.
   PubMed Web of Science ®Google Scholar
• Tsai GE, Lane HY, Yang P, Chong MY, Lange N. 2004. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 55:452–456.
   PubMed Web of Science ®Google Scholar
• Tsai GE, Lin PY. 2009. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des. 16:522–537.
   Web of Science ®Google Scholar
• Tsai GE, Yang P, Chung LC, Lange N, Coyle JT. 1998. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 44:1081–1089.
   PubMed Web of Science ®Google Scholar
• Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, et al. 2014. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: A randomized, double-blind, proof-of-concept study. JAMA Psychiatry. 71:637–646.
   PubMed Web of Science ®Google Scholar
• Van den Berghe-Snorek S, Stankovich MT. 1985. Thermodynamic control of D-amino acid oxidase by benzoate binding. J Biol Chem. 260:3373–3379.
   PubMed Web of Science ®Google Scholar
• Verrall L, Burnet PW, Betts JF, Harrison PJ. 2010. The neurobiology of D-amino acid oxidase and its involvement in schizophrenia. Mol Psychiatry. 15:122–137.
   PubMed Web of Science ®Google Scholar
• Weiser M, Heresco-Levy U, Davidson M, Javitt DC, Werbeloff N, Gershon AA, et al. 2012. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry. 73:e728–e734.
   PubMedGoogle Scholar